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Patients with generalized atrophic benign epidermolysis
bullosa often show decreased expression of type XVII
collagen, a transmembrane hemidesmosomal protein
encoded by COL17A1. This report documents a novel
splice-site mutation in COL17A1 in a patient with gener-
alized atrophic benign epidermolysis bullosa, and applies
a new methodology to define and characterize the
resulting mRNA splice variants. Mutational analysis of
COL17A1 identified a maternally inherited G-to-T trans-
version at the –1 position of exon 32. This acceptor
splice-site mutation led to the formation of aberrant
transcripts present at extremely low levels. Based on
our recent finding that cycloheximide stabilized mutant
COL17A1 transcripts in keratinocytes homozygous for a
frameshift mutation, the effects of the splice-site mutation
on splicing of COL17A1 transcripts were determined
using reverse transcriptase polymerase chain reaction of
Mutations at either the 59 (donor) or the 39 (acceptor)splice sites of intron/exon junctions disrupt exonsplicing and result in exon skipping or activationof nearby cryptic splice sites (Berget, 1995; Maquat,1996). Detection of abnormally spliced transcripts
is important for defining the effects of a splice-site mutation on the
processing of pre-mRNA; however, such aberrant transcripts may
occur at low levels because they often encode premature termination
codons (PTC) and are degraded rapidly through nonsense-mediated
mRNA decay (Maquat, 1996).
Generalized atrophic benign epidermolysis bullosa (GABEB) is an
autosomal recessive, generally nonlethal subepithelial blistering disease
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total RNA from keratinocytes incubated for 2.5 h in the
presence or absence of 10 µg cycloheximide per ml.
Using this approach, an abnormally spliced transcript
was identified that contains an extra 264 bases upstream
from exon 32, resulting in a premature termination codon
27 bp downstream from the cryptic splice site. Three
other splice variants, including one derived from the
skipping of exon 32, were also identified. These results
indicate the usefulness of cycloheximide treatment in
evaluating the abnormal processing of mRNA due to
splice-site mutations, because: (i) aberrant splicing often
generates a premature termination codon, (ii) transcripts
with premature termination codons can occur at low or
undetectable levels due to nonsense-mediated mRNA
decay, and (iii) the levels of these transcripts can be
increased by cycloheximide. Key words: collagen/epidermal
basement membrane/premature termination codon/RNA spli-
cing. J Invest Dermatol 110:165–169, 1998
of skin and mucous membranes (Darling et al, 1998). By immuno-
fluorescence microscopy, most GABEB patients show decreased or
absent type XVII collagen in their epidermal basement membranes
(Jonkman et al, 1995, 1996; Pohla-Gubo et al, 1995) and recent studies
of such patients have identified mutations in COL17A1 (McGrath
et al, 1995, 1996a, b; Darling et al, 1997; Gatalica et al, 1997; Jonkman
et al, 1997; Schumann et al, 1997; Chavanas et al, 1997). Most
COL17A1 mutations characterized to date are nonsense mutations or
insertion/deletion mutations that lead to PTC and extremely low or
undetectable COL17A1 mRNA (McGrath et al, 1995; Darling et al,
1997; Schumann et al, 1997; Chavanas et al, 1997). In keratinocytes
homozygous for a frameshift mutation that results in a downstream
PTC, we showed that the levels of COL17A1 mRNA could be
increased by pretreatment with cycloheximide (Darling et al, 1997).
This report documents a novel splice-site mutation in COL17A1 in a
patient with GABEB, and demonstrates the utility of cycloheximide
pretreatment in the identification and characterization of abnormally
spliced keratinocyte mRNA transcripts that result from this type
of mutation.
MATERIALS AND METHODS
Patient characteristics The patient, a 19 y old Austrian male with a history
of generalized blistering since birth (case 8, Hintner and Wolff, 1982), has
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incomplete diffuse scalp alopecia, sparse body, pubic, and axillary hair, and
pitted, discolored teeth. Blisters have predominated on hands, feet, and face.
Large melanocytic nevi have developed at sites of blistering. His parents are
unrelated and do not show any features of GABEB. He has no siblings.
Immunofluorescence microscopy studies of intact patient skin showed markedly
diminished amounts of type XVII collagen but normal staining for other
structural proteins (Pohla-Gubo et al, 1995).
Analysis of keratinocyte protein and mRNA Patient and normal (control)
keratinocytes were cultured and analyzed in immunoprecipitation and northern
blot studies as previously described (Darling et al, 1997). In selected experiments,
keratinocytes were incubated at 37°C for 2.5 h with 10 µg cycloheximide per ml.
Mutation analysis DNA was isolated from the blood of the proband and
his parents (Sambrook et al, 1989). All 56 exons of COL17A1 (GenBank
no. M91669) were amplified by polymerase chain reaction (PCR) using primers
based on flanking intronic sequences (Gatalica et al, 1997). To amplify exon
32, the 59-AGCTGAGAGGTCCAAGGATG-39 and 59-TCCTAAGGT-
GCTTCTCACGA-39 primers were used. Heteroduplex analysis of the entire
gene for the mother, the father, and the proband was performed using hydrolink
gels [Hydrolink mutation detection enhancement (MDE) Gel, J.T. Baker,
Phillipsburg, NJ] and conformation-sensitive gel electrophoresis (CSGE). PCR
products showing a heteroduplex were cloned into the pNoTA/T7 vector
(PrimePCRTM Cloning System, 5 Prime → 3 Prime, Boulder, CO) and
sequenced using an ABI PrismTM automated sequencer (Perkin Elmer, Branch-
burg, NJ). A splice-site mutation was detected adjacent to exon 32 (see Results
and Discussion). This mutation, which results in a new restriction site for Nla
III (New England Biolabs, Beverly, MA), was confirmed in genomic DNA
using restriction endonuclease digestion (Darling et al, 1997). Nla III digestion
was also performed on PCR-amplified DNA from 50 unrelated healthy control
subjects (DNA, a gift from Drs. Sherri Bale and John Compton, NIAMS, NIH,
Bethesda, MD).
Because the paternally inherited mutation was not detected in heteroduplex
analysis of paternal and proband DNA using both MDE and CSGE gels,
additional studies were performed. Eight previously described mutations in
COL17A1 were screened using restriction enzyme digestion (McGrath et al,
1995, 1996a, b; Darling et al, 1997; Gatalica et al, 1997). Reverse transcriptase
polymerase chain reaction (RT-PCR) of total RNA from patient-cultured
keratinocytes was used to amplify eight overlapping regions of COL17A1.
These were sequenced from both 59 and 39 ends as well as internal sites. To
fill gaps, an additional 13 exons amplified from genomic DNA were also
sequenced. Sequences were analyzed manually and using computer software
(Sequencher 3.0, Gene Codes, Ann Arbor, MI).
RT-PCR Aliquots (µ0.5 µg) of total RNA from patient- and control-
cultured keratinocytes were mixed with random hexamers, reverse transcribed,
combined with primers for COL17A1, and amplified by PCR (GeneAmp
RNA PCR®, Perkin Elmer). The primer pair initially used for amplification
of COL17A1 cDNA corresponded to nucleotides 2017–2037 and 2540–2560
(59-CCTGGATCTGGAGAGAAAGG-39 and 59-GACAGTGAGCATCGAT-
GACC-39 within exons 23 and 25, respectively). cDNA corresponding to
different COL17A1 mRNA transcripts were obtained using RNA from
cycloheximide-treated keratinocytes. These were gel purified using GENE-
CLEAN II® (BIO 101, La Jolla, CA), cloned, and sequenced. To confirm exon
skipping, RT-PCR was carried out using an upstream primer that extended
from exon 31 into the first two bases of exon 33 (59-GACCCAG-
GAAAGCCAGGA-39). As controls, an upstream primer of either the normal
sequence from exon 31 (59-CTGGAGAGACCCAGGAAAGCCA) or the
normal sequence from exon 31 to the first two bases of exon 32 (59-
GACCCAGGAAAGCCAGGT-39) were used. Abnormally spliced COL17A1
transcripts were confirmed by restriction enzyme digestion (Hinf I, Alw26 I,
Dde I, Msp I) (New England Biolabs).
RESULTS AND DISCUSSION
Type XVII collagen protein and mRNA are markedly decreased
in a patient with GABEB Immunoprecipitation studies of biosynthet-
ically radiolabeled patient keratinocytes found no evidence of type
XVII collagen but expected amounts of bullous pemphigoid antigen
1 (Fig 1A). In contrast, both proteins were identified in immunopre-
cipitation studies of control keratinocyte extracts. Northern blot studies
found markedly decreased levels of 6.0 kb COL17A1 mRNA in the
patient’s keratinocytes compared with control keratinocytes (Fig 1B).
Pretreatment of the patient’s keratinocytes with cycloheximide
increased the amount of normally sized COL17A1 mRNA. Densitome-
try was used to quantitate this change relative to the β-actin control
and revealed a 1.4–1.9-fold increase in GABEB keratinocytes (n 5 2).
Figure 1. GABEB keratinocytes show undetectable type XVII collagen
and decreased COL17A1 mRNA. (A) Cellular extracts from biosynthetically
radiolabeled GABEB keratinocytes were immunoprecipitated using preimmune
rabbit serum (lane 1), rabbit anti-sera to type XVII collagen (lane 2), or rabbit
anti-sera to bullous pemphigoid antigen 1 (BPAG1) (lane 3). Lane 2 shows no
evidence of type XVII collagen or a truncated protein. A band of µ230 kDa,
corresponding to BPAG1, is visible in lane 3. (B) Northern blot study of total
RNA extracted from cultured GABEB or normal keratinocytes preincubated
for 2.5 h in the presence (1) or absence (–) of 10 µg cycloheximide (CHX)
per ml. COL17A1 mRNA is decreased in GABEB keratinocytes as compared
with normal human foreskin. In GABEB keratinocytes, cycloheximide increases
COL17A1 mRNA. Equivalent loading of the RNA is shown by the similar
relative intensity of the bands using a probe for β-actin.
Cycloheximide had no effect on the levels of COL17A1 transcripts in
normal keratinocytes.
Mutation analysis reveals an acceptor splice-site mutation in
COL17A1 CSGE (as well as MDE) analysis of the PCR-amplified
DNA narrowed the candidate region for the maternally inherited
mutation in COL17A1 to the region of exon 32 (Fig 2A). This PCR
product of 347 bp is comprised of exon 32 (27 bp) along with parts
of flanking introns 31 and 32. Cloning and sequencing showed the
presence of a G-to-T transversion at the –1 position of exon 32
(Fig 2B), changing the 39 acceptor splice site from an AG to an AT.
This mutation involves a nucleotide that is 100% conserved within the
acceptor splice-site consensus sequence, suggesting that it would alter
splicing of COL17A1 mRNA. Indeed, if one calculates a relative score
for these splice sites, using a formula based on the conserved nucleotide
sequences with top-ranked splice sites scoring up to 100 (Shapiro and
Senapathy, 1987), the normal acceptor splice site for exon 32 scores
93.6 whereas the mutant sequence scores 77.6.
This G-to-T transversion results in a new restriction endonuclease
site for Nla III (CATG/N in the mutant where the substituted
nucleotide is underlined and the cleavage site is indicated by a slash).
Thus, the PCR product with the normal sequence is cleaved to 310
and 37 bp, whereas in the mutant allele the 310 bp fragment is further
cleaved to 182 and 128 bp. Nla III digests of PCR-amplified DNA
from the father or unrelated control showed bands expected for
individuals homozygous for the normal allele, whereas digests of
amplified DNA from the mother or proband showed bands expected
for individuals with one normal and one mutant allele (Fig 2C). Nla
III digestion of amplified DNA from 50 unrelated healthy individuals
found no evidence of this transversion (data not shown), indicating
that this is not a silent polymorphism.
Analysis of all 56 exons of COL17A1 by MDE and CSGE failed to
uncover a candidate region for the paternally inherited mutation. To
evaluate the possibility of a de novo mutation in this proband, all faint
and even questionable heteroduplexes observed in these studies were
sequenced. All exons in question (specifically exons 5, 11, 24, and 47)
were shown to possess the normal sequence. In addition, eight
previously described mutations in COL17A1 were not present in the
proband. Finally, sequencing eight overlapping COL17A1 cDNA as
well as 13 specific exons (to complete this full-length analysis and
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Figure 2. Identification of a maternally inherited
mutation at the 39 acceptor splice site of exon
32. (A) CSGE of exon 32 with its flanking intronic
regions demonstrates a heteroduplex band (→) in
addition to a homoduplex band using DNA from
the mother and the proband, but only a homoduplex
band in the father and control individual. (B)
Nucleotide sequencing of exon 32 shows the
consensus AG at the acceptor splice site adjacent to
exon 32 in the normal, but an AT in the mutant
allele. (Note: The different nucleotide numbers in
these two chromatograms relate to the first nucleotide
counted by an automated sequencer in analysis of
reactions performed on different days and do not
represent corresponding sites in the two sequences.)
(C) Verification of the mutation by the introduction
of a new Nla III site in the mutant. The PCR
product from the father or unrelated control is cleaved
into bands of 310 and 37 bp. The PCR product
from the mother or the proband is cleaved into
bands of 310, 182, 128, and 37 bp, as expected for
individuals with one normal and one mutant allele.
clarify all ambiguities) again failed to identify a second mutation. The
inability to find the second mutation may have related to limitations
in screening for the mutation, difficulties in identifying a heterozygous
point mutation using automated sequencing, or a mutation in the
promoter region of the gene (the latter accounting for the low
COL17A1 mRNA levels as well as the lack of change in its cDNA).
It is clear, however, that the proband has a second genetic lesion,
either paternally inherited or arising de novo, because the proband’s
mother, also heterozygous for the splice-site mutation, was clinically
unaffected.
The acceptor splice-site mutation results in four mutant
COL17A1 transcripts The effects of the acceptor splice mutation
on splicing of COL17A1 transcripts were studied by RT-PCR, using
primers spanning exons 23 through 35. The expected product of
544 bp was obtained using total RNA from normal keratinocytes
(Fig 3). This band was also predominant using total RNA from the
patient, most likely representing amplification of RNA from the
paternally inherited allele. When GABEB keratinocytes were incubated
with cycloheximide prior to isolating the RNA, a band at about 800 bp
was evident, suggesting the presence of an intronic cryptic splice site
upstream from the mutation. This band was consistently demonstrated
in four separate RT-PCR experiments using total RNA from GABEB
keratinocytes preincubated with cycloheximide, but was barely detect-
able in GABEB keratinocytes without pretreatment (Fig 3). This
suggested that this new transcript contained a PTC. Moreover, it
provided a means of identifying the transcript, as larger amounts were
available for further study.
Cloning and sequencing of the µ800 bp product showed that this
band, 808 bp in size, resulted from a cryptic splice site within intron
31, located 264 bp upstream from the normal splice site (mutant
transcript 1 in Fig 4). Restriction enzyme digestion was used to
confirm that splicing at this site accounted for the 808 bp band seen
on the gel; splicing at the cryptic site results in the introduction of a
new restriction endonuclease site for Hinf I [normal transcript
CAGGTCT (last three nucleotides exon 31 followed by first four
nucleotides exon 32) versus cryptic splice transcript CAGATTC (last
three nucleotides exon 31 followed by first four nucleotides intron 31
at cryptic splice site), which contains the recognition sequence for Hinf
I of G/ANTC] (data not shown). Thus, the predominant transcript
derived from 2441–1 G→T results from a cryptic splice site located
in the intron upstream from the mutation. Splicing at this site results
in a PTC 27 bp downstream (Fig 4), and low levels of this transcript
unless cells are incubated with cycloheximide (Fig 3). The use of
cycloheximide, therefore, was instrumental not only in the identifica-
Figure 3. The acceptor splice-site mutation causes abnormal processing
of COL17A1 pre-mRNA, demonstrated in patient keratinocytes
preincubated in the presence of cycloheximide. Primers spanning the
mutation were used in RT-PCR studies performed using RNA from patient
or normal keratinocytes cultured in the presence (1) or absence (–) of
cycloheximide. For a control, reverse transcriptase was omitted (No RT), using
RNA from patient keratinocytes preincubated with cycloheximide. RNA from
both patient and normal keratinocytes yields the normal transcript of 544 bp.
An additional, abnormally large RT-PCR product of about 800 bp is visualized
using RNA from patient keratinocytes preincubated with cycloheximide.
Identical results were obtained in four separate RT-PCR experiments.
tion and cloning of this transcript, but also in predicting the presence
of a PTC.
Cloning mutant transcript 1 incidentally yielded three cDNA that
were smaller than the expected 800 bp of this transcript. These cDNA
corresponded to the normal transcript, mutant transcript 2, and mutant
transcript 4 (Fig 4). These transcripts were not evident in ethidium
bromide stained gels. Transcript 3 was demonstrated during RT-PCR
experiments designed to specifically amplify transcript 4 (see below).
Moreover, the presence of transcript 3 was predicted based on inspection
for an acceptor consensus sequence. This splice site, 9 bp downstream
from the normal splice site, scores 87.2 (Shapiro and Senapathy, 1987),
consistent with preference for this splice site over the mutated splice
site. Transcript 2, originating from cryptic splicing 69 bp upstream
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Figure 4. Normal and aberrant splicing
of COL17A1 exon 32 in patient
keratinocytes. Sequencing of RT-PCR
products revealed four mutant transcripts, three
produced from splicing at cryptic splice sites
and one from skipping of exon 32. The different
patterns of splicing are shown by the diagonal
lines connecting regions spliced together. The
restriction enzymes used to confirm the
identities of the normal transcript as well as
mutant transcripts 3 and 4 are shown at the top
of the figure (→ indicate cleavage sites).
from the mutation, results in a PTC 57 bp downstream from the
cryptic site (Fig 4). Scoring of this site yields 85.8 (Shapiro and
Senapathy, 1987).
Transcript 4 is derived from skipping of exon 32. This transcript,
like transcripts 2 and 3, was undetectable on ethidium bromide
stained gels of the original RT-PCR product. To confirm the presence
of transcript 4, RT-PCR was performed using an upstream
primer that bridged the exon skip. Using total RNA from the patient’s
keratinocytes, a band of the expected size for transcript 4 was obtained
(data not shown). In addition, a band slightly smaller than the normal
transcript was also visualized, corresponding to transcript 3. Bands for
transcripts 3 and 4 were not evident using total RNA from normal
keratinocytes. As controls, RT-PCR was performed using an upstream
primer either located within exon 31 or bridging exons 31 and 32.
These resulted in amplification of the normal sized transcript using
RNA from normal keratinocytes, as well as in patient keratinocytes as
expected based on amplification of the paternally inherited allele (data
not shown). Restriction enzyme digestion was used to confirm the
identities of mutant transcripts 3 and 4, using an enzyme that cleaved
the normal transcript but not mutant transcripts 3 and 4 (Alw26 I), an
enzyme that cleaved the normal transcript and mutant transcript 3 but
not 4 (Dde I), or an enzyme that cleaved all three transcripts (Msp I).
It should be noted that, unlike transcripts 1 and 2, the splicing of
transcripts 3 and 4 is in-frame, and would be expected to result in the
production of proteins missing 3 or 9 amino acids, respectively. As
these transcripts do not result in PTC, one would expect that their
levels would not be altered by cycloheximide. Accordingly, no change
in the intensity of these bands was observed in RT-PCR studies using
total RNA isolated from GABEB keratinocytes preincubated in the
presence of cycloheximide (data not shown). The fact that these
transcripts are produced in such low levels is consistent with the
immunoprecipitation studies showing no evidence of detectable type
XVII collagen in this patient’s keratinocytes.
This report documents a novel G-to-T acceptor splice-site mutation
in COL17A1 at the –1 position of exon 32 in a patient with GABEB.
This report also shows the utility of cycloheximide in determining the
effects of this splice-site mutation on splicing. In a prior study, we showed
how cycloheximide could be used to enhance RNA-based methods of
mutation detection (Darling et al, 1997). In the current manuscript,
we show that cycloheximide facilitated the identification of mutant
transcripts resulting from a splice-site mutation. Numerous splice-site
mutations in various genes have been reported but the effects of such
mutations on pre-mRNA processing have been documented less com-
monly. Furthermore, many papers do not mention that additional aber-
rantly spliced transcripts may be present but undetectable due to
nonsense-mediated mRNA decay. Our paper investigated this largely
ignored possibility. Finally, patients with splice-site mutations frequently
show low levels of mutant transcripts. Our paper provides a possible
explanation for these findings. To illustrate this point, a recent paper,
published subsequent to our submission, nicely documented the first
splice-site mutation in COL17A1 (Chavanas et al, 1997). Like us, these
authors foundmarkedly reduced levels ofCOL17A1mRNAbynorthern
blot; however, in contrast to our study, Chavanas et al found only a mutant
transcript resulting from in-frame exon skipping. Our demonstration that
the predominant transcript derived from the splice-site mutation in our
patient resulted in a PTC sheds light on the cause of the markedly reduced
COL17A1 mRNA in such cases. Incubating cells with and without
cycloheximide prior to isolating RNA may be widely applicable to
RT-PCR studies where nonsense-mediated mRNA decay hinders the
detection of the effects of mutations on processing of mRNA.
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